
ProQR Therapeutics (PRQR) Stock Forecast & Price Target
ProQR Therapeutics (PRQR) Analyst Ratings
Bulls say
ProQR Therapeutics NV is positioned favorably due to its promising Axiomer RNA base-editing platform, which is anticipated to yield positive clinical data from its first-in-human studies, potentially enhancing the company's valuation. Furthermore, the company’s management maintains confidence in its financial stability, with a cash position sufficient to sustain operations into mid-2027, thereby allowing for continued development of its RNA-based therapeutics pipeline. The possibility of expedited clinical advancements could lead to significant stock price appreciation as proof of concept data emerges from human trials.
Bears say
ProQR Therapeutics NV reported a significant increase in net loss for the quarter, reaching -€12.2 million with an earnings per share (EPS) of (€0.12), compared to a loss of -€2.7 million and an EPS of (€0.03) for the same period in 2024, highlighting ongoing financial challenges. The company is heavily reliant on the outcomes of its future Phase Ib/II/III clinical studies, where negative results could exert downward pressure on its stock performance. Furthermore, potential advancements in alternative treatment methods for the diseases addressed by ProQR could jeopardize the competitiveness of its existing therapies, introducing additional uncertainty to its market position.
This aggregate rating is based on analysts' research of ProQR Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
ProQR Therapeutics (PRQR) Analyst Forecast & Price Prediction
Start investing in ProQR Therapeutics (PRQR)
Order type
Buy in
Order amount
Est. shares
0 shares